The Ki-67 index and survival in non-small cell lung cancer: A review and relevance to positron emission tomography

Cancer Journal

Volumn 8, Issue 3, 2002, Pages 222-233

  Pugsley, Jeffrey M ^a   Schmidt, Rodney A ^a   Vesselle, Hubert ^a  

^a UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

Author keywords

Cellular proliferation; Ki 67 protein; Non small cell lung cancer; Positron emission tomography; Prognosis

Indexed keywords

FLUORODEOXYGLUCOSE F 18; KI 67 ANTIGEN; TUMOR MARKER; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT; TUMOR ANTIGEN;

CANCER DIAGNOSIS; CANCER STAGING; CANCER SURVIVAL; CELL PROLIFERATION; CORRELATION ANALYSIS; HIGH RISK PATIENT; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RECURRENT DISEASE; REVIEW; CHEMISTRY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; LUNG TUMOR; LYMPH NODE METASTASIS; METHODOLOGY; PATHOLOGY; PROGNOSIS; SCINTISCANNING;

ANTIGENS, NEOPLASM; CARCINOMA, NON-SMALL-CELL LUNG; FLUORODEOXYGLUCOSE F18; HUMANS; KI-67 ANTIGEN; LUNG NEOPLASMS; LYMPHATIC METASTASIS; NEOPLASM STAGING; PROGNOSIS; RADIOPHARMACEUTICALS; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0036583717     PISSN: 15289117     EISSN: 1540336X     Source Type: Journal    
DOI: 10.1097/00130404-200205000-00003     Document Type: Review

References (67)

1. Greenlee RT, Murray T, Bolden S et al. Cancer statistics, 2000. CA Cancer J Clin 2000;50:7-33.
2. Mountain CF. Revisions in the International System for Staging Lung Cancer. Chest 1997;111:1710-1717.
3. Mitsudomi T, Hamajima N, Ogawa M et al. Prognostic significance of p53 alterations in patients with non-small-cell lung cancer: a meta-analysis. Clin Cancer Res 2000;6:4055-4063.
4. Harpole DH Jr, Herndon JE 2nd, Wolfe WG et al. A prognostic model of recurrence and death in stage I non-small cell lung cancer utilizing presentation, histopathology, and oncoprotein expression. Cancer Res 1995;55:51-56.
5. Macchiarini P, Fontanini G, Hardin MJ et al. Blood vessel invasion by tumor cells predicts recurrence in completely resected T1 N0 M0 non-small-cell lung cancer. J Thorac Cardiovasc Surg 1993;106:80-89.
6. Takise A, Kodama T, Shimosato Y et al. Histopathologic prognostic factors in adenocarcinomas of the peripheral lung less than 2 cm in diameter. Cancer 1988;61:2083-2088.
7. Dazzi H, Thatcher N, Hasleton PS et al. DNA analysis by flow cytometry in nonsmall cell lung cancer: relationship to epidermal growth factor receptor, histology, tumour stage and survival. Respir Med 1990;84:217-223.
8. Filderman AE, Silvestri GA, Gatsonis C et al. Prognostic significance of tumor proliferative fraction and DNA content in stage I non-small cell lung cancer. Am Rev Respir Dis 1992;146:707-710.
9. ten Velde GP, Schutte B, Vermeulen A et al. Flow cytometric analysis of DNA ploidy level in paraffin-embedded tissue of non-small-cell lung cancer. Eur J Cancer Clin Oncol 1988;24:455-460.
10. Volm M, Hahn EW, Mattern J et al. Five-year follow-up study of independent clinical and flow cytometric prognostic factors for the survival of patients with non-small cell lung carcinoma. Cancer Res 1988;48:2923-2928.
11. Ishida T, Kaneko S, Akazawa K et al. Proliferating cell nuclear antigen expression and argyrophilic nucleolar organizer regions as factors influencing prognosis of surgically treated lung cancer patients. Cancer Res 1993;53:5000-5003.
12. Ebina M, Steinberg SM, Mulshine JL et al. Relationship of p53 overexpression and up-regulation of proliferating cell nuclear antigen with the clinical course of non-small cell lung cancer. Cancer Res 1994;54:2496-2503.
13. Fontanini G, Macchiarini P, Pepe S et al. The expression of proliferating cell nuclear antigen in paraffin sections of peripheral, node-negative non-small cell lung cancer. Cancer 1992;70:1520-1527.
14. Macchiarini P, Fontanini G, Hardin MJ et al. Relation of neovascularisation to metastasis of non-small-cell lung cancer. Lancet 1992;340:145-146.
15. Schwarting R. Little missed markers and Ki-67. Lab Invest 1993;68:597-599.
16. McCormick D, Hall PA. The complexities of proliferating cell nuclear antigen. Histopathology 1992;21:591-594.
17. Hall PA, Levison DA, Woods AL et al. Proliferating cell nuclear antigen (PCNA) immunolocalization in paraffin sections: an index of cell proliferation with evidence of deregulated expression in some neoplasms. J Pathol 1990;162:285-294.
18. Gerdes J, Lemke H, Baisch H et al. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol 1984;133:1710-1715.
19. Schluter C, Duchrow M, Wohlenberg C et al. The cell proliferation-associated antigen of antibody Ki-67: a very large, ubiquitous nuclear protein with numerous repeated elements, representing a new kind of cell cycle-maintaining proteins. J Cell Biol 1993;123:513-522.
20. Scholzen T, Gerdes J. The Ki-67 protein: from the known and the unknown. J Cell Physiol 2000;182:311-322.
21. Rudolph P, Peters J, Lorenz D et al. Correlation between mitotic and Ki-67 labeling indices in paraffin- embedded carcinoma specimens. Hum Pathol 1998;29:1216-1222.
22. Cattoretti G, Becker MH, Key G et al. Monoclonal antibodies against recombinant parts of the Ki-67 antigen (MIB 1 and MIB 3) detect proliferating cells in microwave-processed formalin-fixed paraffin sections. J Pathol 1992;168:357-363.
23. Cummings TJ, Provenzale JM, Hunter SB et al. Gliomas of the optic nerve: histological, immunohistochemical (MIB-1 and p53), and MRI analysis. Acta Neuropathol (Berl) 2000;99:563-570.
24. Zlotta AR, Schulman CC. Biological markers in superficial bladder tumors and their prognostic significance. Urol Clin North Am 2000;27:179-189, xi-xii.
25. Indinnimeo M, Cicchini C, Stazi A et al. Immunohistochemical assessment of Ki-67 as prognostic cellular proliferation marker in anal canal carcinoma. J Exp Clin Cancer Res 2000;19:471-475.
26. Vansteenkiste JF, Stroobants SG, Dupont PJ et al. Prognostic importance of the standardized uptake value on (18)F-fluoro-2-deoxyglucose-positron emission tomography scan in non-small-cell lung cancer: an analysis of 125 cases. Leuven Lung Cancer Group. J Clin Oncol 1999;17:3201-3206.
27. Ahuja V, Coleman RE, Herndon J et al. The prognostic significance of fluorodeoxyglucose positron emission tomography imaging for patients with nonsmall cell lung carcinoma. Cancer 1998;83:918-924.
28. Higashi K, Ueda Y, Ayabe K et al. FDG PET in the evaluation of the aggressiveness of pulmonary adenocarcinoma: correlation with histopathological features. Nucl Med Commun 2000;21:707-714.
29. Vesselle H, Schmidt RA, Pugsley JM et al. Lung cancer proliferation correlates with [F-18]fluorodeoxyglucose uptake by positron emission tomography. Clin Cancer Res 2000;6:3837-3844.
30. Duhaylongsod FG, Lowe VJ, Patz EF et al. Lung tumor growth correlates with glucose metabolism measured by fluoride-18 fluorodeoxyglucose positron emission tomography. Ann Thorac Surg 1995;60:1348-1352.
31. Mankoff DA, Shields AF, Graham MM et al. Kinetic analysis of 2-[carbon-11]thymidine PETimaging studies: compartmental model and mathematical analysis. J Nucl Med 1998;39:1043-1055.
32. Shields AF, Grierson JR, Dohmen BM et al. Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nat Med 1998;4:1334-1336.
33. Vander Borght T, Pauwels S, Lambotte L et al. Brain tumor imaging with PET and 2-[carbon-11]thymidine. J Nucl Med 1994;35:974-982.
34. Demarchi LM, Reis MM, Palomino SA et al. Prognostic values of stromal proportion and PCNA, Ki-67, and p53 proteins in patients with resected adenocarcinoma of the lung. Mod Pathol 2000;13:511-520.
35. Kaplan EL, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481.
36. Hayashi Y, Fukayama M, Koike M et al. Cell-cycle analysis detecting endogenous nuclear antigens: comparison with BrdU-in vivo labeling and an application to lung tumors. Acta Pathol Jpn 1993;43:313-319.
37. Dazzi C, Cariello A, Maioli P et al. Prognostic and predictive value of intratumoral microvessels density in operable non-small-cell lung cancer. Lung Cancer 1999;24:81-88.
38. Hommura F, Dosaka-Akita H, Mishina T et al. Prognostic significance of p27KIP1 protein and ki-67 growth fraction in non-small cell lung cancers. Clin Cancer Res 2000;6:4073-4081.
39. Ishida H, Irie K, Itoh T et al. The prognostic significance of p53 and bcl-2 expression in lung adenocarcinoma and its correlation with Ki-67 growth fraction. Cancer 1997;80:1034-1045.
40. Giatromanolaki A, Gorgoulis V, Chetty R et al. C-erbB-2 oncoprotein expression in operable non-small cell lung cancer. Anticancer Res 1996;16:987-993.
41. Komaki R, Milas L, Ro JY et al. Prognostic biomarker study in pathologically staged N1 non-small cell lung cancer. Int J Radiat Oncol Biol Phys 1998;40:787-796.
42. Puglisi F, Aprile G, Bruckbauer M et al. Combined analysis of MIB-1 and thyroid transcription factor-1 predicts survival in non-small cell lung carcinomas. Cancer Lett 2001;162:97-103.
43. Giaccone G, van Ark-Otte J, Scagliotti G et al. Differential expression of DNA topoisomerases in non-small cell lung cancer and normal lung. Biochim Biophys Acta 1995;1264:337-346.
44. D'Amico TA, Aloia TA, Moore MB et al. Molecular biologic substaging of stage I lung cancer according to gender and histology. Ann Thorac Surg 2000;69:882-886.
45. Harpole DH Jr, Richards WG, Herndon JE 2nd et al. Angiogenesis and molecular biologic substaging in patients with stage I non-small cell lung cancer. Ann Thorac Surg 1996;61:1470-1476.
46. Cagini L, Monacelli M, Giustozzi G et al. Biological prognostic factors for early stage completely resected non-small cell lung cancer. J Surg Oncol 2000;74:53-60.
47. Mehdi SA, Etzell JE, Newman NB et al. Prognostic significance of Ki-67 immunostaining and symptoms in resected stage I and II non-small cell lung cancer. Lung Cancer 1998;20:99-108.
48. Pence JC, Kerns BJ, Dodge RK et al. Prognostic significance of the proliferation index in surgically resected non-small-cell lung cancer. Arch Surg 1993;128:1382-1390.
49. Scagliotti GV, Micela M, Gubetta L et al. Prognostic significance of Ki67 labelling in resected non small cell lung cancer. Eur J Cancer 1993;3:363-365.
50. Shiba M, Kohno H, Kakizawa K et al. Ki-67 immunostaining and other prognostic factors including tobacco smoking in patients with resected nonsmall cell lung carcinoma. Cancer 2000;89:1457-1465.
51. D'Amico TA, Massey M, Herndon JE 2nd et al. A biologic risk model for stage I lung cancer: immunohistochemical analysis of 408 patients with the use of ten molecular markers. J Thorac Cardiovasc Surg 1999;117:736-743.
52. Giatromanolaki A, Koukourakis M, O'Byrne K et al. Prognostic value of angiogenesis in operable non-small cell lung cancer. J Pathol 1996;179:80-88.
53. Molino A, Micciolo R, Turazza M et al. Ki-67 immunostaining in 322 primary breast cancers: associations with clinical and pathological variables and prognosis. Int J Cancer 1997;74:433-437.
54. Jansen RL, Hupperets PS, Arends JW et al. MIB-1 labelling index is an independent prognostic marker in primary breast cancer. Br J Cancer 1998;78:460-465.
55. Aaltomaa S, Lipponen P, Vesalainen S et al. Value of Ki-67 immuno-labelling as a prognostic factor in prostate cancer. Eur Urol 1997;32:410-415.
56. Borre M, Bentzen SM, Nerstrom B et al. Tumor cell proliferation and survival in patients with prostate cancer followed expectantly. J Urol 1998;159:1609-1614.
57. Petrowsky H, Sturm I, Graubitz O et al. Relevance of Ki-67 antigen expression and K-ras mutation in colorectal liver metastases. Eur J Surg Oncol 2001;27:80-87.
58. Arai T, Kuroishi T, Saito Y et al. Tumor doubling time and prognosis in lung cancer patients: evaluation from chest films and clinical follow-up study. Japanese Lung Cancer Screening Research Group. Jpn J Clin Oncol 1994;24:199-204.
59. Usuda K, Saito Y, Sagawa M et al. Tumor doubling time and prognostic assessment of patients with primary lung cancer. Cancer 1994;74:2239-2244.
60. Tirindelli-Danesi D, Teodori L, Mauro F et al. Prognostic significance of flow cytometry in lung cancer: a 5-year study. Cancer 1987;60:844-851.
61. Korkolopoulou P, Christodoulou P, Lazaris A et al. Prognostic implications of aberrations in p16/pRb pathway in urothelial bladder carcinomas: a multivariate analysis including p53 expression and proliferation markers. Eur Urol 2001;39:167-177.
62. MacGrogan G, Jollet I, Huet S et al. Comparison of quantitative and semiquantitative methods of assessing MIB-1 with the S-phase fraction in breast carcinoma. Mod Pathol 1997;10:769-776.
63. Rao J, Abella-Columna E, Pounds TR et al. Prevalence of metastatic disease and impact of PET on management in staging lung cancer: a clinical series of 400 patients. J Nucl Med 2000;41[suppl]:75P.
64. Saunders CA, Dussek JE, O'Doherty MJ et al. Evaluation of fluorine-18-fluorodeoxyglucose whole body positron emission tomography imaging in the staging of lung cancer. Ann Thorac Surg 1999;67:790-797.
65. Weder W, Schmid RA, Bruchhaus H et al. Detection of extrathoracic metastases by positron emission tomography in lung cancer. Ann Thorac Surg 1998;66:886-892; discussion 892-893.
66. Pisters KM. The role of chemotherapy in early-stage (stage I and II) resectable non-small cell lung cancer. Semin Radiat Oncol 2000;10:274-279.
67. Vansteenkiste J, Stroobants S, Hoekstra C. 18Fluoro-2-deoxyglucose positron emission tomography (PET) in the assessment induction chemotherapy (IC) in stage IIIa-N2 NSCLC: a multicenter prospective study. Proc ASCO 2001;37:313a.